These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24882259)

  • 1. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.
    Gul Z; Bashir Q; Cremer M; Yusuf SW; Gunaydin H; Arora S; Slone S; Nieto Y; Sherwani N; Parmar S; Shah N; Dinh YT; Hosing CM; Popat UR; Kebriaei P; Shpall EJ; Giralt SA; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2015 Feb; 56(2):533-5. PubMed ID: 24882259
    [No Abstract]   [Full Text] [Related]  

  • 2. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
    Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
    [No Abstract]   [Full Text] [Related]  

  • 3. Tandem bone marrow transplantation in multiple myeloma.
    Chng WJ
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
    Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e59-63. PubMed ID: 24378319
    [No Abstract]   [Full Text] [Related]  

  • 5. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
    Bashir Q; Shah N; Parmar S; Wei W; Rondon G; Weber DM; Wang M; Orlowski RZ; Thomas SK; Shah J; Qureshi SR; Dinh YT; Popat U; Anderlini P; Hosing C; Giralt S; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2012 Jan; 53(1):118-22. PubMed ID: 21780997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of transplant in multiple myeloma.
    Barlogie B
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):604-6. PubMed ID: 16167043
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma.
    Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP
    Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
    Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
    Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
    Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC; Poi MJ
    Mol Carcinog; 2019 Dec; 58(12):2327-2339. PubMed ID: 31544312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
    Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
    Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma.
    Holstein SA; Liu H; McCarthy PL
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1113-29. PubMed ID: 25459182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
    Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare case of interstitial pneumonitis after tandem high-dose melphalan conditioning and autologous stem cell transplantation in multiple myeloma.
    Buxhofer-Ausch V; Ruckser R; Kier P; Habertheuer KH; Zelenka P; Tatzreiter G; Ausch C; Schmid I; Hruby W; Reiner-Concin A; Sebesta C; Ogris E; Hinterberger-Fischer M; Hinterberger W
    Eur J Haematol; 2004 Aug; 73(2):143-6. PubMed ID: 15245515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
    Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH;
    Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Harousseau JL; Moreau P
    N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
    [No Abstract]   [Full Text] [Related]  

  • 20. Melphalan desensitization following immediate hypersensitivity in a patient undergoing conditioning for autologous hematopoietic cell transplantation.
    Ganetsky A; Takach PA; Lynch DM; Krause TM; Teh JS; Stadtmauer EA; Castells M; Weiss BM
    J Allergy Clin Immunol Pract; 2016; 4(3):555-6. PubMed ID: 26883541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.